Skip to main content
SpringerLink
Log in

Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Conditional survival estimates provide useful prognostic information for cancer survivors. The objective of this study was to determine conditional survival estimates for melanoma patients with substages of stage III disease.

Materials and Methods

A retrospective analysis of 760 patients who underwent lymphadenectomy for node-positive melanoma was conducted, and patients were stratified into substages: IIIA, IIIB, and IIIC. The 5-year conditional disease-free survival (DFS) and disease-specific survival (DSS) were calculated following lymphadenectomy using the methods of Kaplan and Meier and were reassessed for survivors on an annual basis. Multivariate Cox regression models were used to calculate adjusted conditional DFS and DSS accounting for age, gender, tumor histology, and extracapsular extension.

Results

For patients with IIIA, IIIB, and IIIC disease, 5-year conditional DSS from treatment to year 5 improved from 78% to 90%, 54% to 79%, and 39% to 78%, respectively. For 5-year conditional DFS over the same period, the estimates increased from 65% to 79%, 37% to 81%, and 26% to 92%, respectively. Male patients experienced decreased 5-year conditional DSS and DFS across all substages, with the most pronounced effect on DSS in stage IIIC. Multivariate analysis demonstrated that survival differences among stage IIIC patients based on histologic subtype and extracapsular extension decreased over time.

Conclusions

Conditional survival estimates are more optimistic and realistic for cancer survivors than traditional survival estimates over time. For node-positive melanoma survivors, 5-year conditional DFS and DSS improve significantly over time. These estimates are critical to treatment decisions and non-treatment-related planning for both clinicians and patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kaplan EL. Nonparametric estimator from incomplete observation J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  2. Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol. 1994;10:2–6.

    Article  CAS  PubMed  Google Scholar 

  3. Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer. 2001;92:2211–9.

    Article  CAS  PubMed  Google Scholar 

  4. Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. Cancer. 1995;76:237–42.

    Article  CAS  PubMed  Google Scholar 

  5. Bouvier AM, Remontet L, Hedelin G, Launoy G, Jooste V, Grosclaude P, et al. Conditional relative survival of cancer patients and conditional probability of death: a French national database analysis. Cancer. 2009;115:4616–24.

    Article  PubMed  Google Scholar 

  6. Merrill RM, Henson DE, Barnes M. Conditional survival among patients with carcinoma of the lung. Chest. 1999;116:697–703.

    Article  CAS  PubMed  Google Scholar 

  7. Skuladottir H, Olsen JH. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003;21:3035–40.

    Article  PubMed  Google Scholar 

  8. Wang SJ, Emery R, Fuller CD, Kim JS, Sittig DF, Thomas CR. Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer. 2007;10:153–8.

    Article  PubMed  Google Scholar 

  9. Merrill RM, Henson DE, Ries LA. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum. 1998;41:1097–106.

    Article  CAS  PubMed  Google Scholar 

  10. Wang SJ, Fuller CD, Emery R, Thomas CR. Conditional survival in rectal cancer: a SEER database analysis. Gastrointest Cancer Res. 2007;1:84–9.

    PubMed  Google Scholar 

  11. Choi M, Fuller CD, Thomas CR, Jr., Wang SJ. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol. 2008;109:203–9.

    Article  PubMed  Google Scholar 

  12. Merrill RM, Bird JS. Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control. 2002;13:435–43.

    Article  PubMed  Google Scholar 

  13. Alanee S, Shukla A. Paediatric testicular cancer: an updated review of incidence and conditional survival from the surveillance, epidemiology and end results database. BJU Int. 2009;104:1280–3.

    Article  PubMed  Google Scholar 

  14. Fuller CD, Wang SJ, Thomas CR, Jr., Hoffman HT, Weber RS, Rosenthal DI. Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973–1998. Cancer.2007;109:1331–43.

    Article  PubMed  Google Scholar 

  15. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 1999;85:485–91.

    Article  CAS  PubMed  Google Scholar 

  16. Hwang SL, Yang YH, Lieu AS, Chuang MC, Chang SJ, Chang YY, et al. The conditional survival statistics for survivors with primary supratentorial astrocytic tumors. J Neurooncol. 2000;50:257–64.

    Article  CAS  PubMed  Google Scholar 

  17. Lin CL, Lieu AS, Lee KS, Yang YH, Kuo TH, Hung MH, et al. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol. 2003;60:402–6.

    Article  CAS  PubMed  Google Scholar 

  18. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010 [Epub ahead of print].

  19. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008.

  20. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. AJCC cancer staging manual. 6th edn. New York: Springer-Verlag; 2002.

    Google Scholar 

  21. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.

    CAS  PubMed  Google Scholar 

  22. Delman KA, Lee JE. Therapeutic neck dissection for melanoma. Oper Tech Gen Surg. 2006;8:103–11.

    Article  Google Scholar 

  23. McMasters KM, Wong SL, Tyler DS, Balch CM, Thompson JF. Axillary and epitrochlear lymph node dissection for melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, Atkins MB, Thompson JF, editors Cutaneous melanoma. 5th ed. St. Louis: Quality Medical Publishing, Inc.; 2009. p. 447–70.

  24. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006;64:106–13.

    PubMed  Google Scholar 

  25. Cox DR. Regression models and life tables. J R Statistical Soc. 1972;B34:187–220.

    Google Scholar 

  26. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239–41.

    Article  Google Scholar 

  27. Donovan RJ, Carter OB, Byrne MJ. People’s perceptions of cancer survivability: implications for oncologists. Lancet Oncol. 2006;7:668–75.

    Article  PubMed  Google Scholar 

  28. Noorda EM, van Kreij RH, Vrouenraets BC, Nieweg OE, Muller M, Kroon BB, et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol. 2007;33:776–82.

    CAS  PubMed  Google Scholar 

  29. Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104:2565–76.

    Article  PubMed  Google Scholar 

  30. Memorial Sloan-Kettering Cancer Center. Prediction tools. 2008. http://www.mskcc.org/nomograms. Accessed 20 July 2009.

  31. Artificial Neural Networks in Prostate Cancer Project. Prostate calculator. 2009. http://www.prostatecalculator.org/. Accessed 20 July 2009.

  32. Washington University in St. Louis. Prognostigram. 2009. http://oto2.wustl.edu/clinepi/prog.html. Accessed 20 July 2009.

  33. Wang SJ. Survival prediction tools. 2008. http://www.ohsu.edu/ohsuedu/academic/som/radmedicine/predict.cfm. Accessed 20 July 2009.

  34. University of Texas M D Anderson Cancer Center. Clinical calculators. 2008. http://www.mdanderson.org/education-and-research/resources-for-professionals/clinical-tools-and-resources/clinical-calculators/index.html. Accessed 20 July 2009.

  35. Cleveland Clinic Lerner Research Institute. Risk calculators. 2009. http://www.lerner.ccf.org/qhs/risk_calculator.php. Accessed 20 July 2009.

  36. Ravdin P. Adjuvant! 2008. http://www.adjuvantonline.com. Accessed 20 July 2009.

  37. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol. 2009;27:5938–43.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This project was supported in part by Grant No. 1 R01 CA127328-01 (Cormier, PI) from National Cancer Institute, National Institutes of Health. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Health.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Tawnya L. Bowles MD, Yan Xing MD, MS, PhD, Chung-Yuan Hu MPH, Kristi S. Mungovan MS, PA-C, Robert L. Askew MPH, George J. Chang MD, Jeffrey E. Gershenwald MD, Jeffrey E. Lee MD, Paul F. Mansfield MD, Merrick I. Ross MD & Janice N. Cormier MD, MPH

Authors
  1. Tawnya L. Bowles MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Xing MD, MS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chung-Yuan Hu MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kristi S. Mungovan MS, PA-C
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert L. Askew MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George J. Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeffrey E. Gershenwald MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeffrey E. Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul F. Mansfield MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Merrick I. Ross MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Janice N. Cormier MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janice N. Cormier MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bowles, T.L., Xing, Y., Hu, CY. et al. Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease. Ann Surg Oncol 17, 2015–2023 (2010). https://doi.org/10.1245/s10434-010-1051-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1051-y

Keywords

Search

Navigation